Table 1.

Important publications on Neurotramitter Modulators as AD therapeautics

Neurotransmitters	Therapeutics	References
Cholinergic	Tacrine	Nagabukuro et al., 2005; Minarini et al., 2013; Alonso et al., 2005; Guzior et al., 2015
	Donepezil	Cacabelos, 2007
	Galanthamine	Hopkins et al., 2012; Albuquerque et al., 2001
	Rivastigmine	Rodrigues Simoes et al., 2014; Toda et al., 2003
	Xanthostigmine	Belluti et al., 2005
	Pyrrolo-isoxazole derivatives	Anand and Singh, 2012; Razavi et al., 2013;
Glutametargic	Memantine	Golde, 2006; Farlow et al., 2008; Cummings, 2007; Danysz and Parsons, 2012; Dominguez et al., 2011; Prokselj et al., 2013
GABAergic	Etazolate	Marcade et al., 2008
	Gabapentin	Cooney et al., 2013
Serotonergic	Lecozotan	Schechter et al., 2005
	Tandospirone and Buspirone	Miller et al., 1992; Sumiyoshi et al., 2007
	PRX-3140, PF-04995274 and RQ-00000009 (RQ-9)	Ramirez et al., 2014
	SB-742457	Maher-Edwards et al., 2010
	Lu-AE-58054 (SGS-518)	Ramirez, 2013
	Dimebon	Bezprozvanny, 2010
	SSRI	Nagy et al., 2004
Histaminergic	Carebastine and mepyramine	Mizuguchi et al., 2012
	R-(alpha)-methylhistamine	Motawaj et al., 2010
	Pyrilamine	Kharmate et al., 2007
	Thioperamide and ondansetron	Passani and Blandina, 1998
	Chlorpheniramine	Baronio et al., 2014
Adrenergic	SCH58261	Melani et al., 2003